Literature DB >> 26542150

Effects of Levetiracetam, Carbamazepine, Phenytoin, Valproate, Lamotrigine, Oxcarbazepine, Topiramate, Vinpocetine and Sertraline on Presynaptic Hippocampal Na(+) and Ca(2+) Channels Permeability.

María Sitges1, Luz María Chiu2, Ronald C Reed3.   

Abstract

Ion channels are targets of various antiepileptic drugs. In cerebral presynaptic nerve endings Na(+) and Ca(2+) channels are particularly abundant, as they control neurotransmitter release, including the release of glutamate (Glu), the most concentrated excitatory amino acid neurotransmitter in the brain. Several pre-synaptic channels are implicated in the mechanism of action of the pro-convulsive agent, 4-aminopyridine (4-AP). In the present study the effects of levetiracetam and other established and newer (vinpocetine) anti-epileptic drugs, as well as of the anti-depressant, sertraline on the increase in Ca(2+) induced by 4-AP in hippocampal isolated nerve endings were investigated. Also the effects of some of the anti-seizure drugs on the selective increase in Ca(2+) induced by high K(+), or on the selective increase in Na(+) induced by veratridine were tested. Sertraline and vinpocetine effectively inhibited the rise in Ca(2+) induced by 4-AP, which was dependent on the out-in Na(+) gradient and tetrodotoxin sensitive. Carbamazepine, phenytoin, lamotrigine and oxcarbazepine inhibited the rise in Ca(2+) induced by 4-AP too, but at higher concentrations than sertraline and vinpocetine, whereas levetiracetam, valproic acid and topiramate did not. The three latter antiepileptic drugs also failed in modifying other responses mediated by the activation of brain presynaptic Na(+) or Ca(2+) channels, including Glu release. This indicates that levetiracetam, valproic acid and topiramate mechanisms of action are unrelated with a decrease in presynaptic Na(+) or Ca(2+) channels permeability. It is concluded that depolarized cerebral isolated nerve endings represent a useful tool to unmask potential antiepileptic drugs targeting presynaptic Na(+) and/or Ca(2+) channels in the brain; such as vinpocetine or the anti-depressant sertraline, which high effectiveness to control seizures in the animal in vivo has been demonstrated.

Entities:  

Keywords:  4-aminopirydine; Anti-epileptic drugs; Calcium channels; Glu release; Hippocampus nerve endings; Sodium channels

Mesh:

Substances:

Year:  2015        PMID: 26542150     DOI: 10.1007/s11064-015-1749-0

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  47 in total

1.  Selective suppression of the slow-inactivating potassium currents by nootropics in molluscan neurons.

Authors:  Julia V Bukanova; Elena I Solntseva; Vladimir G Skrebitsky
Journal:  Int J Neuropsychopharmacol       Date:  2002-09       Impact factor: 5.176

2.  Calcium channels coupled to glutamate release identified by omega-Aga-IVA.

Authors:  T J Turner; M E Adams; K Dunlap
Journal:  Science       Date:  1992-10-09       Impact factor: 47.728

3.  Presynaptic action potential amplification by voltage-gated Na+ channels in hippocampal mossy fiber boutons.

Authors:  Dominique Engel; Peter Jonas
Journal:  Neuron       Date:  2005-02-03       Impact factor: 17.173

4.  Study on the possible involvement of protein kinases in the modulation of brain presynaptic sodium channels; comparison with calcium channels.

Authors:  M Sitges; F Peña; L M Chiu; A Guarneros
Journal:  Neurochem Int       Date:  1998-02       Impact factor: 3.921

5.  Neocortical hyperexcitability in a genetic model of absence seizures and its reduction by levetiracetam.

Authors:  Giovanna D'Arcangelo; Margherita D'Antuono; Virginia Tancredi; Massimo Avoli
Journal:  Epilepsia       Date:  2006-07       Impact factor: 5.864

6.  omega-Aga IVA selectively inhibits the calcium-dependent fraction of the evoked release of [3H]GABA from synaptosomes.

Authors:  M Sitges; L M Chiu
Journal:  Neurochem Res       Date:  1995-09       Impact factor: 3.996

7.  K(+)-channel openers suppress epileptiform activities induced by 4-aminopyridine in cultured rat hippocampal neurons.

Authors:  Kiyoaki Kobayashi; Yukio Nishizawa; Kohei Sawada; Hiroo Ogura; Masayuki Miyabe
Journal:  J Pharmacol Sci       Date:  2008-12-11       Impact factor: 3.337

8.  Comorbidity between temporal lobe epilepsy and depression: a [18F]MPPF PET study.

Authors:  A Lothe; A Didelot; A Hammers; N Costes; M Saoud; F Gilliam; P Ryvlin
Journal:  Brain       Date:  2008-09-02       Impact factor: 13.501

9.  Effects of pentylenetetrazole and 4-aminopyridine on the auditory brainstem response (ABR) and on the hearing sensitivity in the guinea pig in vivo.

Authors:  Vladimir Nekrassov; María Sitges
Journal:  Epilepsy Res       Date:  2003-03       Impact factor: 3.045

10.  Vinpocetine prevents 4-aminopyridine-induced changes in the EEG, the auditory brainstem responses and hearing.

Authors:  Maria Sitges; V Nekrassov
Journal:  Clin Neurophysiol       Date:  2004-12       Impact factor: 3.708

View more
  11 in total

Review 1.  Elucidating opportunities and pitfalls in the treatment of experimental traumatic brain injury to optimize and facilitate clinical translation.

Authors:  Patricia B de la Tremblaye; Darik A O'Neil; Megan J LaPorte; Jeffrey P Cheng; Joshua A Beitchman; Theresa Currier Thomas; Corina O Bondi; Anthony E Kline
Journal:  Neurosci Biobehav Rev       Date:  2017-05-30       Impact factor: 8.989

2.  The Effect of Non-Gabapentinoid Anticonvulsants on Sensorimotor Recovery After Human Spinal Cord Injury.

Authors:  Freda M Warner; Catherine R Jutzeler; Jacquelyn J Cragg; Bobo Tong; Lukas Grassner; Frank Bradke; Fred Geisler; John K Kramer
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

3.  Amelioration of a neurodevelopmental disorder by carbamazepine in a case having a gain-of-function GRIA3 variant.

Authors:  Kohei Hamanaka; Keita Miyoshi; Jia-Hui Sun; Keisuke Hamada; Takao Komatsubara; Ken Saida; Naomi Tsuchida; Yuri Uchiyama; Atsushi Fujita; Takeshi Mizuguchi; Benedicte Gerard; Allan Bayat; Berardo Rinaldi; Mitsuhiro Kato; Jun Tohyama; Kazuhiro Ogata; Yun Stone Shi; Kuniaki Saito; Satoko Miyatake; Naomichi Matsumoto
Journal:  Hum Genet       Date:  2022-01-15       Impact factor: 4.132

4.  Comparison between cannabidiol and sertraline for the modulation of post-traumatic stress disorder-like behaviors and fear memory in mice.

Authors:  Xiao Han; Xiankui Song; Dake Song; Guanbo Xie; Hongyan Guo; Ning Wu; Jin Li
Journal:  Psychopharmacology (Berl)       Date:  2022-04-09       Impact factor: 4.530

5.  Can a Selective Serotonin Reuptake Inhibitor Act as a Glutamatergic Modulator?

Authors:  Marcos Emilio Frizzo
Journal:  Curr Ther Res Clin Exp       Date:  2017-07-08

6.  A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection.

Authors:  Jane P F Bai; Theodore Sakellaropoulos; Leonidas G Alexopoulos
Journal:  Toxins (Basel)       Date:  2017-03-10       Impact factor: 4.546

7.  Sub-additive (antagonistic) interaction of lacosamide with lamotrigine and valproate in the maximal electroshock-induced seizure model in mice: an isobolographic analysis.

Authors:  Jarogniew J Łuszczki; Maria Kondrat-Wróbel; Mirosław Zagaja; Sławomir Karwan; Hubert Bojar; Zbigniew Plewa; Magdalena Florek-Łuszczki
Journal:  Pharmacol Rep       Date:  2020-06-07       Impact factor: 3.024

8.  Episodic Vestibulocerebellar Ataxia Associated with a CACNA1G Missense Variant.

Authors:  José Gazulla; Silvia Izquierdo-Alvarez; Emilio Ruiz-Fernández; Alba Lázaro-Romero; José Berciano
Journal:  Case Rep Neurol       Date:  2021-06-11

9.  Polygonogram with isobolographic synergy for three-drug combinations of phenobarbital with second-generation antiepileptic drugs in the tonic-clonic seizure model in mice.

Authors:  Jarogniew J Łuszczki; Dominika Podgórska; Justyna Kozińska; Marek Jankiewicz; Zbigniew Plewa; Mateusz Kominek; Dorota Żółkowska; Magdalena Florek-Łuszczki
Journal:  Pharmacol Rep       Date:  2020-10-06       Impact factor: 3.024

10.  Vinpocetine Attenuates Ischemic Stroke Through Inhibiting NLRP3 Inflammasome Expression in Mice.

Authors:  Dong Han; Jue Wang; Lulu Wen; Miao Sun; Hang Liu; Yan Gao
Journal:  J Cardiovasc Pharmacol       Date:  2020-12-22       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.